Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Merck Sharp & Dohme LLC
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07060807CT.gov A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | — | Recruiting | — | — | — |
NCT06797635CT.gov Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | — | Recruiting | — | — | — |
NCT06686394CT.gov Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Patritumab Deruxtecan (this asset) | Merck Sharp & Dohme LLC | P3 | B · 60 |
| Docetaxel | Universitas Airlangga | P4 | BB |
| Tamoxifen | Eli Lilly and Company | P3 | BB |
| Letrozole | Fujian Cancer Hospital | P4 | BB |
| Exemestane | Fujian Cancer Hospital | P4 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P4 | BB |
| Adriamycin | Merck Sharp & Dohme LLC | P4 | BB |
| Palbociclib | Eli Lilly and Company | P4 | BB |
| Microporous Polysaccharide Hemospheres | Fundación para la Investigación del Hospital Clínico de Valencia | P4 | BB |
+42 more in the Breast Neoplasm cohort
Other indications for Patritumab Deruxtecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 66 |
| Non-Small Cell Squamous Lung Carcinoma | — | P2 | B · 57 |
| Breast Cancer | — | P2 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Patritumab Deruxtecan in Breast Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/patritumab-deruxtecan-breast-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →